Inhibrx Biosciences (INBX) Non Operating Interest Expenses (2023 - 2026)
Powered by 
Analysis
Inhibrx Biosciences (INBX) Non Operating Interest Expenses (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Inhibrx Biosciences | 1.92 Bn | 1.92 Bn | - | 5.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.69 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Sep 30, 2025 | 3.18 Mn |
| Jun 30, 2025 | 3.14 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Jun 30, 2024 | 5.36 Mn |
| Mar 31, 2024 | 8.13 Mn |
| Dec 31, 2023 | 8.22 Mn |
| Sep 30, 2023 | 8.15 Mn |
| Jun 30, 2023 | 7.91 Mn |